T. Ohno

发表

Population pharmacokinetics and exposure-response relationship of a muscarinic receptor antagonist, imidafenacin.

Takafumi Ouchi, S. Nakade, Chihiro Hasegawa, 2013, Drug metabolism and pharmacokinetics.

Brain translocator protein occupancy by ONO‐2952 in healthy adults: A Phase 1 PET study using [11C]PBR28

R. Narendran, W. Frankle, K. Duffy, 2017, Synapse.

The Use of Population Pharmacokinetic and Pharmacodynamic Modeling and Simulation in Anti-Osteoporotic Drug Development: A Perspective

I. Ieiri, Chihiro Hasegawa, T. Ohno, 2014 .

Evaluation of an intestinal pressure-controlled colon delivery capsules prepared by a dipping method.

Y. Jeong, N. Shibata, K. Takada, 2001, Journal of controlled release : official journal of the Controlled Release Society.

The prediction of human response to ONO‐4641, a sphingosine 1‐phosphate receptor modulator, from preclinical data based on pharmacokinetic–pharmacodynamic modeling

S. Nakade, Chihiro Hasegawa, T. Ohno, 2010, Biopharmaceutics & drug disposition.

Benefit‐risk assessment of nivolumab 240 mg flat dose relative to 3 mg/kg Q2W regimen in Japanese patients with advanced cancers

J. Gobburu, M. Osawa, A. Roy, 2019, Cancer science.

Application of Eudragit P‐4135F for the delivery of ellagic acid to the rat lower small intestine

Y. Jeong, K. Takeuchi, N. Shibata, 2001, The Journal of pharmacy and pharmacology.

The prevalence and disease burden of severe eosinophilic asthma in Japan

T. Kuroda, M. Mishima, H. Matsumoto, 2019, The Journal of asthma : official journal of the Association for the Care of Asthma.

The Prevalence, Characteristics, and Patient Burden of Severe Asthma Determined by Using a Japan Health Care Claims Database.

T. Ishii, C. Ito, T. Ohno, 2019, Clinical therapeutics.

Modeling and simulation of bone mineral density response from a phase 2 study of ONO‐5334, a new cathepsin K inhibitor, to support dose selection in osteoporosis

I. Ieiri, H. Kastrissios, J. Monteleone, 2014, Journal of clinical pharmacology.

Population pharmacokinetic and pharmacodynamic modeling of different formulations of ONO‐5334, cathepsin K inhibitor, in Caucasian and Japanese postmenopausal females

I. Ieiri, Chihiro Hasegawa, T. Ohno, 2014, Journal of clinical pharmacology.

Population pharmacokinetics of landiolol hydrochloride in healthy subjects.

Y. Tanigawara, T. Kunisawa, H. Kasai, 2008, Drug Metabolism and Pharmacokinetics.

Pharmacokinetic-Pharmacodynamic-Efficacy Modeling of ONO-7579, a Novel Pan–Tropomyosin Receptor Kinase Inhibitor, in a Murine Xenograft Tumor Model

R. Harada, T. Ohno, R. Kozaki, 2020, The Journal of Pharmacology and Experimental Therapeutics.

Population pharmacokinetics of pranlukast hydrate dry syrup in children with allergic rhinitis and bronchial asthma.

E. Yukawa, S. Higuchi, S. Ueda, 2006, Drug metabolism and pharmacokinetics.

Application of pressure‐controlled colon delivery capsule to oral administration of glycyrrhizin in dogs

N. Shibata, K. Takada, Y. Yoshikawa, 2001, The Journal of pharmacy and pharmacology.

Effect of Itraconazole on the Pharmacokinetics of Imidafenacin in Healthy Subjects

A. Ohnishi, S. Ueda, S. Ueda, 2008 .

Population pharmacokinetics of aprepitant and dexamethasone in the prevention of chemotherapy-induced nausea and vomiting

Yoshitaka Hashimoto, S. Nakade, T. Ohno, 2008, Cancer Chemotherapy and Pharmacology.

Absorption Enhancing Effect of Labrasol on the Intestinal Absorption of Insulin in Rats

N. Shibata, K. Takada, Y. Yoshikawa, 2002, Journal of drug targeting.

A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies.

G. Salles, M. Dyer, C. Fegan, 2016, Blood.

Adiposity and the risk of rheumatoid arthritis: a systematic review and meta-analysis of cohort studies

D. Aune, T. Ohno, A. Heath, 2020, Scientific Reports.

Novel Platform for Predicting Drug Effects in Patients with Acromegaly: Translational Exposure-Response Evaluation of Growth Hormone–Inhibitory Effect of Octreotide after Growth Hormone–Releasing Hormone Stimulation

Ryusuke Nagasawa, K. Shinozaki, Takuya Nishio, 2021, The Journal of Pharmacology and Experimental Therapeutics.

Characteristics of intestinal absorption and disposition of glycyrrhizin in mice

N. Shibata, K. Takada, Y. Yoshikawa, 2000, Biopharmaceutics & drug disposition.

Characterization of norfloxacine release from tablet coated with a new pH-sensitive polymer, P-4135F.

K. Takada, Y. Yoshikawa, T. Ohno, 1999, Journal of drug targeting.

Absolute bioavailability of imidafenacin after oral administration to healthy subjects.

S. Ueda, S. Nakade, T. Ohno, 2008, British journal of clinical pharmacology.

No effect of imidafenacin, a novel antimuscarinic drug, on digoxin pharmacokinetics in healthy subjects.

A. Ohnishi, Yoshitaka Hashimoto, S. Nakade, 2008, Drug metabolism and pharmacokinetics.

Population pharmacokinetic analysis of a novel muscarinic receptor antagonist, imidafenacin, in healthy volunteers and overactive bladder patients.

S. Nakade, T. Ohno, K. Nakayama, 2008, Drug metabolism and pharmacokinetics.

Effect of Itraconazole on the Pharmacokinetics of Imidafenacin in Healthy Subjects

A. Ohnishi, S. Ueda, S. Nakade, 2008, Journal of clinical pharmacology.